Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Meeting on the Mesa 2020 | Adaptimmune: SPEAR T-cells

Helen Tayton-Martin • 15 Oct 2020
Meeting on the Mesa 2020
Gastroesophageal Junction Adenocarcinoma Head and Neck Cancer Sarcoma ADP-A2M4CD8 SPEAR T-cells
SURPASS

TCR T-cell therapies (SPEAR T-cells) hold the potential to treat a wide range of cancers. In this video, Helen Tayton-Martin, Chief Business Officer, Adaptimmune, Oxford, UK. discusses the SPEAR T-cells currently under development with Adaptimmune. Dr Taytor-Martin goes on to discuss Adaptimmune’s partnership with GlaxoSmithKline (GSK) and recent advances such as the SURPASS trial (NCT04044859) which investigated ADP-A2M4CD8 in HLA-A2+ subjects with MAGE-A4 positive tumors. This interview took place during the 2020 Meeting on the Mesa congress.

More from Helen Tayton-Martin

4:21
T-cells: challenges in bringing to market
Helen Tayton-Martin • 15 Oct 2020
3:12
The cell therapy landscape: disruptive technologies
Helen Tayton-Martin • 15 Oct 2020
1:41
The potential of RegenMed in the oncology space
Helen Tayton-Martin • 15 Oct 2020

Related Videos

1:13
PiggyBac Transposon-generated CAR T-cells in solid tumors
Shigeki Yagyu • 8 Apr 2022
3:06
Targeting solid tumors: SPEAR T-cells & HLA-independent TCRs
Jo Brewer • 7 Apr 2021
1:09
SPEARHEAD-1: ADP-A2M4 in synovial sarcoma and MRCLS
Jo Brewer • 7 Apr 2021
The content of VJRegenMed is intended for healthcare professionals